As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease

Travere Therapeutics recently reported two pivotal trial flops for Filspari, with one threatening the drug’s accelerated approval in IgA nephropathy (IgAN) and the other raising doubts about its chances of tapping into another kidney disease.